Change Is Percolating Through Japan's Pharmaceutical Markets

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Japan' s Changing Pharma Environment
• The Japanese Pharma Landscape
  • Market Size and Demographics
  • Health Care Expenditures Versus Gross Domestic Product
  • Financial Standing of Japanese Domestic Pharma Companies
  • Best-Selling Drugs in Japan
• Measures to Contain Drug Expenditure Costs
  • Biennial Drug Price Revision
  • Price Cuts for Long-Listed Drugs
  • Ongoing Discussions on the Frequency of NHI Price Revisions
• Movement in Japanese Biologics
  • Japanese Pharma Companies Involved in Marketing Biologics
  • Key Marketed Japanese Biologics: Comparative Price and Japanese Sales
  • Japanese Company Pipelines: Late-Stage Biologics
• Growing Acceptance and Use of Generic Drugs
  • The Japanese Government' s Stance on Generics
  • Generics Use by Hospitals with "Flat Sum" Reimbursement Systems
  • New Entrants
  • Outlook for the Generics Market in Japan
• Growing Impact of Foreign Pharmaceutical Companies
  • Multinational Players Strengthen Their Foothold
  • Domestic Companies Face Increasing Competition
  • Geographic Launch Gap for Innovative Drugs Narrows
• Recent Mergers and Acquisitions
  • Chugai and Nippon Roche
  • Daiichi and Sankyo
  • Dainippon and Sumitomo
  • Tanabe and Mitsubishi
  • Yamanouchi and Fujisawa
  • Finding Improved Ways to Compete Effectively
  • Revision of Corporate Law
• Navigating Japan Pharma' s Stormy Waters
  • Mergers and Acquisitions
  • Foreign Companies Operating in Japan
  • Domestic Companies

Figures and Tables

Tables:

• 1. The Changing Business Environment for Japanese Pharma, Circa 2007
• 2. Best-Selling Drugs in Japan, 2005-2006
• 3. Revision Rates for Japanese Reimbursement Prices, 1994-2006
• 4. Percentage Reductions in Average NHI Prices for Leading Pharmaceutical Companies in Japan, 2006
• 5. Percentage of Medical Institutions and Pharmacies That Have Settled Negotiations of Drug Delivery Prices with Wholesalers, July 2006
• 6. Select Japanese Pharma Companies: Biologics Sales in Proportion to Total Worldwide Sales, 2006
• 7. Key Marketed Biologics in Japan: Comparative Price and Japanese Sales, 2006
• 8. Japanese Company Pipelines: Late-Stage Biologics
• 9. Increasing Use of Generics in Diagnostic Procedure Combination Hospitals, Fiscal Years 2004-2006
• 10. Foreign Multinational Players: Select Japanese Market Strategies and Equity Transfers, 2002-2007
• 11. Sales of the Top 15 Companies in the Japanese Ethical Drug Market, Fiscal Years 2003-2006
• 12. Study Council on the Use of Unapproved Drugs: Drugs on the Agenda for Review
• 13. Mergers and Acquisitions of Key Japanese Pharmaceutical Companies, 2002-2007

Figures:

• 1. The Japanese Pharmaceutical Market, Fiscal Years 2002-2006
• 2. Growth of the Elderly Population in Japan, 1980-2006
• 3. Growth Rates: Japan' s National Health Care Expenditures Compared with Its Gross Domestic Product
• 4. Total Market Value of Listed Shares of Japanese Companies, March 2007
• 5. Ratio of Drug Costs to Total Health Care Expenditures in Japan, 1991-2003
• 6. Number of Drugs Launched in the Japanese Market by Major Companies, 2002-2006
• 7. Japanese Company Sales: Domestic and Overseas, 2006